Biomarkers in personalised treatment of renal-cell carcinoma

The Lancet Oncology

Volumn 13, Issue 8, 2012, Pages 751-752

  Shariat, Shahrokh F ^a   Xylinas, Evanguelos ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; CYTOKINE; PAZOPANIB; PLACEBO;

CLINICAL DECISION MAKING; DIAGNOSTIC VALUE; HUMAN; KIDNEY CARCINOMA; LETTER; METASTASIS POTENTIAL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REPRODUCIBILITY; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VALIDATION PROCESS;

ANGIOGENIC PROTEINS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CYTOKINES; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SULFONAMIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84864375941     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70292-9     Document Type: Letter

References (10)

1. Siegel R, Naishadham D, Jemal A Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Sun M, Shariat SF, Cheng C, et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 2011, 60:644-661.
3. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010, 58:398-406.
4. Verma M, Srivastava S New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res 2003, 163:72-84.
5. Winget MD, Baron JA, Spitz MR, et al. Development of common data elements: the experience of and recommendations from the early detection research network. Int J Med Inform 2003, 70:41-48.
6. Shariat SF, Canto EI, Kattan MW, Slawin KM Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 2004, 6:58-72.
7. Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for metastatic renal-cell cancer in patients treated with pazopanib: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012, published online July 2. http://dx.doi.org/10.1016/S1470-2045(12)70241-3.
8. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A Tumor markers in prostate cancer I: blood-based markers. Acta Oncol 2011, 50(suppl 1):61-75.
9. Kattan MW Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003, 95:634-635.
10. Mandrekar SJ, Sargent DJ Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009, 27:4027-4034.